TakaiM, YamauchiT, FujitaK, et al.: Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome. Oncol Lett, 2014; 8:1523–1527.
2.
TamuraK, KawaiY, KiguchiT, et al.: Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol, 2016; 21:996–1003.
3.
KonishiM, PelgrimL, TschirnerA, et al.: Febuxostat improves outcome in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle, 2015; 6:174–180.
4.
OhSH, ChoiSY, ChoiHJ, et al.: The emerging role of xanthine oxidase inhibition for suppression of breast cancer cell migration and metastasis associated with hypercholesterolemia. FASEB J, 2019; 33:7301–7314.
5.
KobyleckiCJ, AfzalS, NordestgaardBG: Plasma urate, cancer incidence, and all-cause mortality: a Mendelian Randomization Study. Clin Chem, 2017; 63:1151–1160.
6.
ItahanaY, HanR, BarbierS, LeiZ, RozenS, ItahanaK: The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. Oncogene, 2015; 34:1799–1810.
7.
VuylstekeV, ChastainLM, MagguGA, BrownC: Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs R D, 2015; 15:227–232.
8.
SakamotoM, MatsutaniD, KayamaY: Possibility of a new therapeutic strategy for left ventricular dysfunction in type 2 diabetes. J Clin Med Res, 2018; 10:799–805.
9.
VialG, ChauvinMA, BendridiN, et al.: Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes, 2015; 64:2254–2264.
10.
WangYR, TianFL, YanMX, et al.: Sulfasalazine inhibits inflammation and fibrogenesis in pancreas via NF-κB signaling pathway in rats with oxidative stress-induced pancreatic injury. Drug Des Dev Ther, 2016; 10:1743–1751.
11.
SleireL, SkeieBS, NetlandIA, et al.: Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion. Oncogene, 2015; 34:5951–5959.
12.
SatoK, TomiokaH, ShimizuT, GondaT, OtaF, SanoC: Type II alveolar cells play roles in macrophage-mediated host innate resistance to pulmonary mycobacterial infections by producing proinflammatory cytokines. J Infect Dis, 2002; 185:1139–1147.
13.
BenmerzougS, MarinhoFV, RoseS, et al.: GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection. Sci Rep, 2018; 8:8652.
14.
ScottJP, JiY, KannanM, WylamME: Inhaled granulocyte-macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis. Eur Respir J, 2018; 51:pii:1702127.
15.
WuUI, OlivierKN, KuhnsDB, et al.: Patients with idiopathic pulmonary nontuberculous mycobacterial disease have normal Th1/Th2 cytokine responses but diminished Th17 cytokine and enhanced granulocyte-macrophage colony-stimulating factor production. Open Forum Infect Dis, 2019; 6:ofz484.
16.
CortesJ, TalpazM, SmithHP, et al.: Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica, 2017; 102:519–528.
SniderL, GengLN, LemmersRJ, et al.: Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet, 2010; 6:e1001181.
19.
BaillyC: Irinotecan: 25 years of cancer treatment. Pharmacol Res, 2019; 148:104398.
20.
WongDVT, Ribeiro-FilhoHV, WanderleyCWS, et al.: SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemother Pharmacol, 2019; 84:287–298.
21.
ChenZ, XuX, PiaoL, ChangS, LiuJ, KongR: Identify old drugs as selective bacterial β-GUS inhibitors by structural based virtual screening and bio-evaluations. Chem Biol Drug Des, 2019. [Epub ahead of print]; DOI: 10.1111/cbdd.13655
22.
KongR, LiuT, ZhuX, et al.: Old drug new use—amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin Cancer Res, 2014; 20:3521–3530.
23.
MorrisonJ, RathoreAPS, MantriCK, AmanSAB, NishidaA, St JohnAL: Transcriptional profiling confirms the therapeutic effects of mast cell stabilization in a Dengue Disease Model. J Virol, 2017; 91. pii: e00617-17.
24.
MalavigeGN, OggGS: Pathogenesis of vascular leak in dengue virus infection. Immunology, 2017; 151:261–269.
ChaoCH, WuWC, LaiYC, et al.: Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage. PLoS Pathog, 2019; 15:e1007625.
27.
DiszháziG, MagyarZÉ, MótyánJA, et al.: Dantrolene requires Mg2+ and ATP To inhibit the ryanodine receptor. Mol Pharmacol, 2019; 96:401–407.
28.
HarrisonGG: Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth, 1975; 47:62–65.
29.
ZamiriN, MasséS, RamadeenA, et al.: Dantrolene improves survival after ventricular fibrillation by mitigating impaired calcium handling in animal models. Circulation, 2014; 129:875–885.
30.
BokhariMM, SpearsDA, LaiPF, et al.: Safety of chronic cardiac ryanodine receptor modulation: a 10-year experience. JACC Clin Electrophysiol, 2018; 4:1480–1481.
31.
BertlettGR: The inhibition of d-amino acid oxidase by benzoic acid and various monosubstituted benzoic acid derivatives. J Am Chem Soc, 1948; 70:1010.
32.
SnyderSH, KimPM: D-amino acids as putative neurotransmitters: focus on D-serine. Neurochem Res, 2000; 25:553–560.
33.
DangYH, MaXC, ZhangJC, et al.: Targeting of NMDA receptors in the treatment of major depression. Curr Pharm Des, 2014; 20:5151–5159.
34.
LaiCH: Sodium benzoate, a D-amino acid oxidase inhibitor, increased volumes of thalamus, amygdala, and brainstem in a drug-naïve patient with major depression. J Neuropsychiatry Clin Neurosci, 2013; 25:E50–E51.
35.
LaiCH, LaneHY, TsaiGE: Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naïve patient with major depression. Biol Psychiatry, 2012; 71:e9–e10.
36.
LambR, OzsvariB, LisantiCL, et al.: Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget, 2015; 6:4569–4584.
37.
SotgiaF, OzsvariB, FiorilloM, De FrancescoEM, BonuccelliG, LisantiMP: A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. Cell Cycle, 2018; 17:2091–2100.
38.
OmuraJ, SatohK, KikuchiN, et al.: ADAMTS8 promotes the development of pulmonary arterial hypertension and right ventricular failure: a possible novel therapeutic target. Circ Res, 2019; 125:884–906.
39.
ZhaoX, YangC, WuJ, NanY: ADAMTS8 targets ERK to suppress cell proliferation, invasion, and metastasis of hepatocellular carcinoma. Onco Targets Ther, 2018; 11:7569–7578.
40.
TofferiJK, JacksonJL, O'MalleyPG: Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum, 2004; 51:9–13.
41.
MoldofskyH, HarrisHW, ArchambaultWT, KwongT, LedermanS: Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol, 2011; 38:2653–2663.
42.
CimolaiN: Cyclobenzaprine: a new look at an old pharmacological agent. Expert Rev Clin Pharmacol, 2009; 2:255–263.
43.
SadowskiI, HashemiFB. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs. Cell Mol Life Sci, 2019; 76:3583–3600.
44.
TenhunenR, TokolaO, LindénIB: Haem arginate: a new stable haem compound. J Pharm Pharmacol, 1987; 39:780–786.
45.
ShankaranP, VlkovaL, LiskovaJ, MelkovaZ: Heme arginate potentiates latent HIV-1 reactivation while inhibiting the acute infection. Antiviral Res, 2011; 92:434–446.
